Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches.

Li H, Bitler BG, Vathipadiekal V, Maradeo ME, Slifker M, Creasy CL, Tummino PJ, Cairns P, Birrer MJ, Zhang R.

Cancer Prev Res (Phila). 2012 Mar;5(3):484-91. doi: 10.1158/1940-6207.CAPR-11-0414. Epub 2011 Dec 5.

2.

Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.

Li H, Cai Q, Godwin AK, Zhang R.

Mol Cancer Res. 2010 Dec;8(12):1610-8. doi: 10.1158/1541-7786.MCR-10-0398. Epub 2010 Nov 29.

3.

NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells.

Garipov A, Li H, Bitler BG, Thapa RJ, Balachandran S, Zhang R.

Mol Cancer Res. 2013 Apr;11(4):360-9. doi: 10.1158/1541-7786.MCR-12-0661. Epub 2013 Jan 29.

4.

EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.

Fu Y, Chen J, Pang B, Li C, Zhao J, Shen K.

Cell Biochem Biophys. 2015 Jan;71(1):105-12. doi: 10.1007/s12013-014-0168-1.

PMID:
25077680
5.

Polycomb repressor complex-2 is a novel target for mesothelioma therapy.

Kemp CD, Rao M, Xi S, Inchauste S, Mani H, Fetsch P, Filie A, Zhang M, Hong JA, Walker RL, Zhu YJ, Ripley RT, Mathur A, Liu F, Yang M, Meltzer PA, Marquez VE, De Rienzo A, Bueno R, Schrump DS.

Clin Cancer Res. 2012 Jan 1;18(1):77-90. doi: 10.1158/1078-0432.CCR-11-0962. Epub 2011 Oct 25.

6.

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.

Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, Koh TL, Yu Q, Chng WJ.

Blood. 2011 Sep 8;118(10):2830-9. doi: 10.1182/blood-2010-07-294827. Epub 2011 Jul 6.

7.

SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK.

Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, Hua X, Landen CN, Birrer MJ, Sánchez-Beato M, Zhang R.

Mol Cancer Res. 2012 Nov;10(11):1462-72. doi: 10.1158/1541-7786.MCR-12-0335. Epub 2012 Sep 10.

8.

MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf¹/cip¹).

Semaan A, Qazi AM, Seward S, Chamala S, Bryant CS, Kumar S, Morris R, Steffes CP, Bouwman DL, Munkarah AR, Weaver DW, Gruber SA, Batchu RB.

Pharm Res. 2011 Dec;28(12):3079-90. doi: 10.1007/s11095-011-0547-x. Epub 2011 Aug 5.

PMID:
21818714
9.

Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.

Sun F, Chan E, Wu Z, Yang X, Marquez VE, Yu Q.

Mol Cancer Ther. 2009 Dec;8(12):3191-202. doi: 10.1158/1535-7163.MCT-09-0479.

10.

Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.

Dreger H, Ludwig A, Weller A, Stangl V, Baumann G, Meiners S, Stangl K.

Hypertension. 2012 Nov;60(5):1176-83. doi: 10.1161/HYPERTENSIONAHA.112.191098. Epub 2012 Sep 10.

11.

Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.

Grimaldi G, Christian M, Steel JH, Henriet P, Poutanen M, Brosens JJ.

Mol Endocrinol. 2011 Nov;25(11):1892-903. doi: 10.1210/me.2011-1139. Epub 2011 Sep 8.

12.

Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.

Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, Xiao L, Wang Z.

Cancer Biol Ther. 2010 Oct 15;10(8):788-95. Epub 2010 Oct 15.

PMID:
20686362
13.

EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.

Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF, Liao YJ, Deng HX, Chen YC, Guan XY, Zeng YX, Kung HF, Xie D.

Carcinogenesis. 2010 Sep;31(9):1576-83. doi: 10.1093/carcin/bgq150. Epub 2010 Jul 28.

PMID:
20668008
14.

MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.

Zhang JG, Guo JF, Liu DL, Liu Q, Wang JJ.

J Thorac Oncol. 2011 Apr;6(4):671-8. doi: 10.1097/JTO.0b013e318208eb35.

15.

Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.

Fujii S, Ochiai A.

Cancer Sci. 2008 Apr;99(4):738-46. doi: 10.1111/j.1349-7006.2008.00743.x.

16.

Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo.

Sarma K, Margueron R, Ivanov A, Pirrotta V, Reinberg D.

Mol Cell Biol. 2008 Apr;28(8):2718-31. doi: 10.1128/MCB.02017-07. Epub 2008 Feb 19.

17.

Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.

Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, Hudson DL, Kaye SB, Brown R.

Mol Cancer Ther. 2011 Feb;10(2):325-35. doi: 10.1158/1535-7163.MCT-10-0788. Epub 2011 Jan 7.

18.

PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer.

Sato T, Kaneda A, Tsuji S, Isagawa T, Yamamoto S, Fujita T, Yamanaka R, Tanaka Y, Nukiwa T, Marquez VE, Ishikawa Y, Ichinose M, Aburatani H.

Sci Rep. 2013;3:1911. doi: 10.1038/srep01911.

19.

EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.

Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, Ching AK, Cheung KF, Wong HK, Tong JH, Jin H, Choy KW, Yu J, To KF, Wong N, Huang TH, Sung JJ.

Cancer Res. 2011 Jun 1;71(11):4028-39. doi: 10.1158/0008-5472.CAN-10-3342. Epub 2011 Apr 21.

20.

Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.

Nakagawa S, Okabe H, Sakamoto Y, Hayashi H, Hashimoto D, Yokoyama N, Sakamoto K, Kuroki H, Mima K, Nitta H, Imai K, Chikamoto A, Watanabe M, Beppu T, Baba H.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S667-75. doi: 10.1245/s10434-013-3135-y. Epub 2013 Jul 26.

PMID:
23887863

Supplemental Content

Support Center